Organisation paid for research Program year 2023 Source: CMS Open Payments

Columbus NCORP

Neither a doctor nor a teaching hospital

Research payments

$341,520

99 payments

Through program year 2023, Columbus NCORP is reported as receiving $341,520 in research payments, across 99 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $5,432 3
2022 Research $95,543 9
2021 Research $98,077 9
2020 Research $137,750 55
2019 Research $4,717 23

Breakdown

Who paid Research payments · program years 2019–2023
  1. Merck Sharp & Dohme Corporation $169,018 74 payments
  2. Alkermes, Inc. $79,720 5 payments
  3. Clovis Oncology, Inc. $73,382 15 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $11,445 1 payment
  5. Genentech, Inc. $7,205 3 payments
  6. pharmaand GmbH $750 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC $117,840 4 payments
  2. A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer $79,720 5 payments
  3. A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) $74,132 16 payments
  4. A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC $39,084 1 payment
  5. X16104: A Phase II Study of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma $11,445 1 payment
  6. A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com $7,205 3 payments
  7. A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy $6,094 68 payments
  8. A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab Mk-3475, NSC 776864 in Addition to Paclitaxel and Carboplatin for Measurable Stage III Or Iva, Stage Ivb Or Recurrent Endometrial Cancer $6,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record